Detecting early Alzheimer's disease using MRI technology
Early Detection Of Alzheimer's Disease With GlucoCEST MRI: A Feasibility Study.
This study is testing a new MRI method to see if it can help detect early signs of Alzheimer's disease in people aged 65 and older, including those with the disease and healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Aberdeen Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Aberdeen) |
| Trial ID | NCT05614310 on ClinicalTrials.gov |
What this trial studies
This observational study aims to improve the early diagnosis of Alzheimer's disease (AD) by utilizing a novel MRI technique called glucose Chemical Exchange Saturation Transfer (glucoCEST). Unlike traditional methods that rely on radioactive tracers and PET imaging, glucoCEST MRI offers a non-invasive and repeatable approach to assess cerebral glucose levels in patients. The study will include individuals aged 65 and older, both diagnosed with AD and healthy controls, to compare glucose metabolism and cognitive function. By identifying early signs of AD, the study seeks to facilitate timely intervention and management.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 65 and older, either diagnosed with Alzheimer's disease or healthy controls with no memory issues.
Not a fit: Patients with a history of diabetes, major strokes, or advanced Alzheimer's disease who cannot provide consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate diagnoses of Alzheimer's disease, allowing for better management and treatment options.
How similar studies have performed: While traditional imaging methods have been widely used, the glucoCEST MRI approach is innovative and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Development phase: Controls (development group) must: * be \> 18 years * consent to the study * not report problems with memory. Clinical phase Patients must: * be ≥ 65 years, * able to provide informed consent to the study * have been clinically diagnosed with AD by the mental health team. Controls must: * be ≥ 65 years * able to provide consent to the study * have a normal score in the ADAS-cog test and the Mini Mental State Examination test (MMSE) * not report problems with memory. Exclusion Criteria: Subjects will not be considered if they: * have a history of diabetes, * have history of a major stroke (mini-stroke/Transient Ischaemic Attacks or lacunar stroke are acceptable), * have contra-indications to MRI scanning such as implantable cardiac devices * have family history in AD, to exclude possible gene mutations associated with AD * have advanced AD who lack the capacity to consent. * Are pregnant (for developmental phase) * are unable to read or speak English
Where this trial is running
Aberdeen
- University of Aberdeen — Aberdeen, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Gordon Waiter, PhD
- Email: g.waiter@abdn.ac.uk
- Phone: +44 (0)1224 438356
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.